Esophageal cancer is the sixth most common cause of cancer‐related death worldwide.
Because of very poor 5‐year survival new therapeutic approaches are mandatory. Erlotinib …

BACKGROUND: Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor
(EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in …

This phase I trial investigates the safety of combining radiation, 5-fluorouracil (5-FU) and
cisplatin with the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, in …

High expression of epidermal growth factor receptor (EGFR) is thought to be correlated with
cell proliferation, invasion, metastasis, resistance to chemoradiotherapy, and poor prognosis …

Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US.
The long-term survival of patients with this cancer remains poor; only 25% of patients …

Background Epidermal growth factor receptor (EGFR) plays a pivotal role in the
pathophysiology of esophageal squamous cell carcinoma (ESCC). However, the clinical …

Purpose: Overexpression of epidermal growth factor receptor (EGFR) in esophageal cancer
is associated with poor prognosis. Preclinical studies indicate synergism between the EGFR …

Esophageal and gastric cancer incidence has been increasing worldwide. Most cases are
diagnosed in advanced stages, and current therapy has not been able to improve the …

4022 Background: Patients with advanced esophageal cancer have a poor prognosis.
Although chemotherapy is often employed as first-line treatment there is no standard therapy …

Purpose: At presentation, most cases of adenocarcinoma of the esophagus (ACE) are
inoperable. Although chemotherapy can prolong survival, patients eventually die as a result …